About pertuzumab + trastuzumab
HER2-targeted monoclonal antibodies
Used for
- Treats HER2-positive early breast cancer with chemotherapy, before or after surgery.
- Treats HER2-positive metastatic breast cancer with docetaxel.
Usual adult dose
Early cancer: 1,200 mg pertuzumab/600 mg trastuzumab initially, then 600 mg/600 mg every 3 weeks. Metastatic cancer: initial dose, then 600 mg/600 mg every 3 weeks; usually with docetaxel.
Common side effects
- Diarrhea, nausea, fatigue, and hair loss
- Injection-site reactions and muscle or joint pain
- Low blood counts and infections
- Heart dysfunction, including reduced pumping ability
Important warnings
- Can cause serious heart problems; heart function requires monitoring.
- Can cause severe allergic or infusion reactions.
- May cause fetal harm; pregnancy testing and effective contraception are important.
- Administered by a healthcare professional under cancer specialist supervision.
Pregnancy
May cause fetal harm. Avoid during pregnancy; effective contraception is recommended during treatment and for 7 months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for 7 months after the last dose.
Interactions
- No major direct drug interactions are established; chemotherapy can add toxicity.
- Anthracyclines may increase heart damage risk, especially after treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.